Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9793411 | 0.85 | TSHR (0.44) | TSHR | |
| SCHEMBL4452909 | 0.73 | — | — | |
| SCHEMBL10496899 | 0.72 | TSHR (0.38) | TSHRALDH1A1 | |
| SCHEMBL10497008 | 0.71 | TSHR (0.37) | TSHR | |
| SCHEMBL2491470 | 0.69 | — | — | |
| SCHEMBL4655237 | 0.67 | TSHR (0.33) | TSHR | |
| SCHEMBL39400 | 0.65 | — | — | |
| SCHEMBL2825581 | 0.65 | — | — | |
| SCHEMBL28863462 | 0.65 | RNPEP (0.33) | TSHR | |
| SCHEMBL4654060 | 0.65 | TSHR (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5284963-A | Reacting 9-amino tetracycline derivative with haloacyl halide in mixture of polar aprotic solvent, inert solvent, base; reacting product under inert atmosphere with nucleophilic amine | AMERICAN CYANAMID COMPANY (US) | 1994-02-08 | — | — | US | claimed |
| EP-2885286-B1 | 2,3-BENZODIAZEPINES | Bayer Pharma AG (DE) | 2017-03-22 | — | — | EP | disclosed |
| EP-2958922-A1 | PYRROLO- AND PYRAZOLO-TRIAZOLODIAZEPINES AS BET-PROTEIN INHIBITORS FOR TREATING HYPERPROLIFERATIVE DISEASES | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-30 | — | — | EP | disclosed |
| EP-2958923-A1 | 4-SUBSTITUTED PYRROLO- AND PYRAZOLO-DIAZEPINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-30 | — | — | EP | disclosed |
| WO-2015121227-A1 | 6,9-DISUBSTITUTED 1-PHENYL-3H-2,3-BENZODIAZEPINES AND THEIR USE AS BROMODOMAIN INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015121230-A1 | 9-SUBSTITUTED 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015121268-A1 | 1-PHENYL-3H-2,3-BENZODIAZEPINES AND THEIR USE AS BROMODOMAIN INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015121226-A1 | 6-SUBSTITUTED 2,3-BENZODIAZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| EP-2885286-A1 | 2,3-BENZODIAZEPINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014128070-A1 | PYRROLO- AND PYRAZOLO-TRIAZOLODIAZEPINES AS BET-PROTEIN INHIBITORS FOR TREATING HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | disclosed |
| US-20090149517-A1 | NOVEL 2-SUBSTITUTED TIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | BAYER SCHERING PHARMA AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| EP-1939185-A1 | New types of hetaryl-phenylendiamin-pyrimidines as protein kinase inhibitors for the treatment of cancer | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-07-02 | — | — | EP | disclosed |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20070191393-A1 | Macrocyclic anilinopyrimidines with substituted sulphoximine as selective inhibitors of cell cycle kinases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1803723-A1 | (2,4,9-TRIAZA-1(2,4)-PYRIMIDINA-3(1,3)-BENZENACYCLONONAPHAN-3^4-YL)-SULFOXIMIDE DERIVATIVES AS SELECTIVE INHIBITORS OF THE AURORA KINASE FOR THE TREATMENT OF CANCER | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-04 | — | — | EP | disclosed |
| EP-0835248-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997001543-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-16 | — | — | WO | disclosed |
| EP-0579071-A2 | Heteroaromatic compounds and plant-protecting agents containing them | BASF Aktiengesellschaft (DE) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | PRKCE, BRAF, PACSIN2 | TSHR 2539/4885ALDH1A1 3892/4885MAPK1 198/4885 |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | CABLES1, CKS2, CDK2AP1 | TSHR 4318/4885ALDH1A1 1535/4885MAPK1 12/4885 |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | CDK2, MKI67, ERBB2 | TSHR 896/4885ALDH1A1 523/4885MAPK1 81/4885 |
| US-20070191393-A1 | Macrocyclic anilinopyrimidines with substituted sulphoximine as selective inhibitors of cell cycle kinases | CCNI, CDK2, CDK1 | TSHR 3381/4885ALDH1A1 3242/4885MAPK1 137/4885 |
| US-20090149517-A1 | NOVEL 2-SUBSTITUTED TIAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | CNR2, TPMT, ABAT | TSHR 304/4885ALDH1A1 487/4885MAPK1 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.